[Isolation of a group of hybrid proteins consisting of tumor necrosis factor alpha and thymosin alpha 1].
Shmelev. V A VA; Bunina. Z F ZF; Kudriavtseva. T Iu TIu; Zinchenko. E V EV; Boldyreva. E F EF; Korobko. V G VG
Key Findings
- Three hybrid proteins were built with thymosin‑alpha‑1 attached to either the N‑ or C‑terminal of TNF‑alpha.
- Plasmids carrying the hybrid genes were unstable in E. coli, but high levels of protein could still be produced under certain conditions.
- Purified hybrid proteins showed different levels of toxicity to L‑929 fibroblast cells, indicating they may be useful for further immunology research.
Practical Outcomes
- This study doesn’t provide any dosage, safety, or protocol information for personal use of thymosin‑alpha‑1. It shows that creating TNF‑alpha/ thymosin‑alpha‑1 hybrids is technically demanding and requires specialized lab equipment, so biohackers should stick to established, commercially available thymosin‑alpha‑1 products if interested in immune support.
Summary
Scientists engineered new hybrid proteins that fuse the immune‑boosting peptide thymosin‑alpha‑1 with tumor necrosis factor, produced them in bacteria, and tested their effects on mouse cells. The work is mostly about lab techniques and cell toxicity, not about how to use thymosin‑alpha‑1 in humans.
Abstract
New plasmid DNA coding for the synthesis of three hybrid proteins differing by the position of alpha 1-thymosin at N- and C-terminals of tumor necrosis factor were optimized and constructed. The instability of plasmids at culturing of E. coli strains stored in solid nutrient media was demonstrated. Newly obtained transformants and preserved cells were cultured, this providing a high level of synthesis of hybrid proteins. The effects of culturing temperature and protein structure on protein solubility were shown. Hybrid proteins were purified by chromatography on hydrophobic anion-exchange carriers and blue agarose in the presence of 7 M urea. After dialysis the proteins displayed different cytotoxicity in L-929 cells and were fit for immunobiological studies.
Study Information
pubmed
1995